Jason Gotlib

Jason Gotlib

UNVERIFIED PROFILE

Are you Jason Gotlib?   Register this Author

Register author
Jason Gotlib

Jason Gotlib

Publications by authors named "Jason Gotlib"

Are you Jason Gotlib?   Register this Author

100Publications

5762Reads

25Profile Views

New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Leuk Lymphoma 2019 Dec 26:1-9. Epub 2019 Dec 26.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1703974DOI Listing
December 2019

World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.

Am J Hematol 2019 Oct;94(10):1149-1167

Division of Hematology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25617DOI Listing
October 2019

A Kindred with a β-Globin Base Substitution [β89(F5)Ser→Arg (AG>AG); : c.270T>G] Resulting in Hemoglobin Vanderbilt.

Hemoglobin 2019 Jul - Sep;43(4-5):273-276. Epub 2019 Oct 28.

Division of Hematology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03630269.2019.1680382DOI Listing
October 2019

Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.

Int J Lab Hematol 2019 Jun 27;41(3):345-352. Epub 2019 Feb 27.

Department of Pathology, Stanford University Medical Center, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12981DOI Listing
June 2019

The new tool "" in advanced systemic mastocytosis.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):127-136

Divisions of Hematology and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245986PMC
November 2018

Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Curr Hematol Malig Rep 2018 10;13(5):407-416

Division of Hematology, Stanford Cancer Institute / Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2324, Stanford, CA, 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0469-3DOI Listing
October 2018

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

Clin Lymphoma Myeloma Leuk 2018 05 2;18(5):e201-e210. Epub 2018 Mar 2.

University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.02.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927833PMC
May 2018

Myelophthisic marrow involved by breast cancer and acute myeloid leukemia.

Blood 2018 03;131(9):1036

Stanford University School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-10-809921DOI Listing
March 2018

SOHO State-of-the-Art Update and Next Questions: MPN.

Clin Lymphoma Myeloma Leuk 2018 01;18(1):1-12

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915302PMC
January 2018

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

J Clin Oncol 2017 Dec 20;35(34):3844-3850. Epub 2017 Sep 20.

Ruben A. Mesa, Mayo Clinic Cancer Center, Scottsdale, AZ; Jean-Jacques Kiladjian, Saint-Louis Hospital (Assistance Publique-Hôpitaux de Paris) and Paris Diderot University, Paris, France; John V. Catalano, Frankston Hospital and Monash University, Melbourne, Victoria, Australia; Timothy Devos, University Hospital Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Miklos Egyed, Kaposi Mor Teaching Hospital, Kaposvar, Hungary; Andrzei Hellmann, Medical University of Gdańsk, Gdańsk, Poland; Donal McLornan, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom; Kazuya Shimoda, University of Miyazaki, Miyazaki, Japan; Elliott F. Winton, Emory University School of Medicine, Atlanta, GA; Wei Deng, Ronald L. Dubowy, and Julia D. Maltzman, Gilead Sciences, Foster City; Jason Gotlib, Stanford Cancer Institute, Stanford, CA; and Francisco Cervantes, Hospital Clinic, Institut D'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.4418
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.4418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553796PMC
December 2017

World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.

Authors:
Jason Gotlib

Am J Hematol 2017 Nov;92(11):1243-1259

Stanford Cancer Institute, Stanford, California 94305-5821.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24880DOI Listing
November 2017

Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in and .

G3 (Bethesda) 2017 10 5;7(10):3295-3303. Epub 2017 Oct 5.

Department of Pathology, Stanford University School of Medicine, California 94305

View Article

Download full-text PDF

Source
http://g3journal.org/lookup/doi/10.1534/g3.117.300141
Publisher Site
http://dx.doi.org/10.1534/g3.117.300141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633380PMC
October 2017

Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Curr Hematol Malig Rep 2017 10;12(5):432-441

Stanford Cancer Institute, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0413-yDOI Listing
October 2017

A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.

Cancer Genet 2017 Oct 10;216-217:10-15. Epub 2017 May 10.

Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2017.05.001DOI Listing
October 2017

Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.

Authors:
Jason Gotlib

Hematol Oncol Clin North Am 2017 08;31(4):643-661

Division of Hematology, Stanford Cancer Institute/Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2324, Stanford, CA 94305-5821, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.04.009DOI Listing
August 2017

A molecular roadmap for midostaurin in mastocytosis.

Authors:
Jason Gotlib

Blood 2017 07;130(2):98-100

STANFORD CANCER INSTITUTE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-05-781237DOI Listing
July 2017

Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.

Am J Hematol 2017 May 24;92(5):E66-E68. Epub 2017 Feb 24.

Division of Hematology-Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24673DOI Listing
May 2017

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.

Br J Haematol 2017 Mar 21;176(6):939-949. Epub 2017 Feb 21.

Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14501DOI Listing
March 2017

How I treat atypical chronic myeloid leukemia.

Authors:
Jason Gotlib

Blood 2017 02 29;129(7):838-845. Epub 2016 Nov 29.

Division of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-08-693630DOI Listing
February 2017

Myeloid neoplasms with eosinophilia.

Blood 2017 02 27;129(6):704-714. Epub 2016 Dec 27.

Division of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-10-695973DOI Listing
February 2017

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

J Natl Compr Canc Netw 2016 12;14(12):1505-1512

From St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Memorial Sloan Kettering Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Stanford Cancer Institute; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; Fox Chase Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Roswell Park Cancer Institute; University of Colorado Cancer Center; University of Michigan Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; UCSF Helen Diller Family Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; Mayo Clinic Cancer Center; University of Wisconsin Carbone Cancer Center; National Comprehensive Cancer Network; Huntsman Cancer Institute at the University of Utah; and Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0162DOI Listing
December 2016

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.

Haematologica 2016 10;101(10):1133-1143

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.146563DOI Listing
October 2016

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

N Engl J Med 2016 Jun;374(26):2530-41

From the Hematology Division, Stanford University School of Medicine-Stanford Cancer Institute, Stanford, CA (J.G.); Faculty of Medical Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (H.C.K.-N.); Department of Pathology, University of New Mexico, Albuquerque (T.I.G.); Mastocytosis Center, Brigham and Women's Hospital, Boston (C.A.); Institute of Pathology, Ludwig-Maximilians-University Munich, Munich (K.S., H.-P.H.), Department of Dermatology and Venereology, University of Cologne, Cologne, and University of Luebeck, Luebeck (K.H.), and Department of Hematology and Oncology, University Hospital Mannheim of the University of Heidelberg, Mannheim (A.R.) - all in Germany; University of Paris Descartes, Institut Imagine INSERM Unité 1163 and Centre National de la Recherche Scientifique ERL8654, Centre de Reference des Mastocytoses, Paris (O.H.); Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus (F.T.A.); Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia (E.H.); Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York (M.J.M.); Novartis Pharmaceuticals, East Hanover, NJ (D.W.S., E.J.S.); Novartis Pharma, Basel, Switzerland (M.V., A.H.L.); and the Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna (P.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513098DOI Listing
June 2016

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Br J Haematol 2016 Apr 4;173(2):253-9. Epub 2016 Apr 4.

Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13946DOI Listing
April 2016

Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.

Authors:
Jason Gotlib

Curr Hematol Malig Rep 2015 Dec;10(4):351-61

Stanford University School of Medicine/Stanford Cancer Institute, 875 Blake Wilbur Drive, Room 2324, Stanford, CA, 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-015-0280-3DOI Listing
December 2015

World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.

Authors:
Jason Gotlib

Am J Hematol 2015 Nov;90(11):1077-89

Stanford Cancer Center, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24196DOI Listing
November 2015

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.

Leuk Lymphoma 2015 Jul 17;56(7):2092-7. Epub 2015 Feb 17.

Department of Leukemia, The University of Texas MD Anderson Cancer Center , Houston, TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.984703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919663PMC
July 2015

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

J Natl Compr Canc Netw 2015 Apr;13(4):424-34

From Northwestern University Feinberg School of Medicine, Chicago, Illinois; Stanford Cancer Institute, Stanford University, Stanford, California; Duke Cancer Institute, Duke University, Durham, North Carolina; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; University of California, San Francisco, San Francisco, California; Johns Hopkins University School of Medicine, Baltimore, Maryland; Moores Cancer Center, UC San Diego, San Diego, California; University of Colorado Cancer Center, Aurora, Colorado; Fred Hutchinson Cancer Research Center, Seattle, Washington; Dana Farber Cancer Institute, Boston, Massachusetts; Memorial Sloan Kettering Cancer Center, New York; New York; Moffitt Cancer Center and Research Institute, Tampa, Florida; The Ohio State University, Columbus, Ohio; Fred & Pamela Buffett Cancer Center, Omaha, Nebraska; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Roswell Park Cancer Institute, Buffalo, New York; Washington University-Siteman Cancer Center, St Louis, Missouri; St. Jude Children's Research Hospital, Memphis, Tennessee; University of Alabama at Birmingham, Birmingham, Alabama; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; Yale University School of Medicine; New Haven, Connecticut; University of Utah, Salt Lake City, Utah; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; City of Hope Cancer Center, Los Angeles, California; The University of Texas MD Anderson Cancer Center, Houston, Texas; and Mayo Clinic Cancer Center, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0058DOI Listing
April 2015

The serum tryptase test: an emerging robust biomarker in clinical hematology.

Expert Rev Hematol 2014 Oct 28;7(5):683-90. Epub 2014 Aug 28.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.955008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603354PMC
October 2014

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Biol Blood Marrow Transplant 2014 Sep 27;20(9):1274-81. Epub 2014 Mar 27.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.03.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465357PMC
September 2014

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.

Authors:
Jason Gotlib

Hematology Am Soc Hematol Educ Program 2013 ;2013:529-37

1Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2013.1.529DOI Listing
July 2014

Altered translation of GATA1 in Diamond-Blackfan anemia.

Nat Med 2014 Jul 22;20(7):748-53. Epub 2014 Jun 22.

1] Division of Hematology and Oncology, Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA. [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [3] Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. [4] Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. [5] Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087046PMC
July 2014

Hereditary erythrocytosis, thrombocytosis and neutrophilia.

Best Pract Res Clin Haematol 2014 Jun 18;27(2):95-106. Epub 2014 Jul 18.

Division of Hematology, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2014.07.002DOI Listing
June 2014

Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study.

Hematol Rep 2014 Apr 23;6(2):5466. Epub 2014 Jun 23.

Division of Hematology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute , CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/hr.2014.5466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091290PMC
April 2014

World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.

Authors:
Jason Gotlib

Am J Hematol 2014 Mar;89(3):325-37

Division of Hematology, Stanford Cancer Center, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23664DOI Listing
March 2014

Two faces of ET: CALR and JAK2.

Blood 2014 Mar;123(10):1438-40

INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-01-547596DOI Listing
March 2014

Chronic Myelogenous Leukemia, Version 1.2014.

J Natl Compr Canc Netw 2013 Nov;11(11):1327-40

From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105PMC
http://dx.doi.org/10.6004/jnccn.2013.0157DOI Listing
November 2013

Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22).

Am J Clin Pathol 2013 Oct;140(4):525-35

Dept of Pathology, Stanford University School of Medicine, 300 Pasteur Dr, MC 5324, Stanford, CA 94086; e-mail:

View Article

Download full-text PDF

Source
https://ajcp.oxfordjournals.org/content/ajcpath/140/4/525.fu
Web Search
http://ajcp.ascpjournals.org/cgi/doi/10.1309/AJCP1Q0YSXEAHNK
Publisher Site
http://dx.doi.org/10.1309/AJCP1Q0YSXEAHNKKDOI Listing
October 2013

Practical management of patients with myelofibrosis receiving ruxolitinib.

Expert Rev Hematol 2013 Oct 2;6(5):511-23. Epub 2013 Oct 2.

Guy's and St. Thomas' NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2013.827413DOI Listing
October 2013

The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Blood 2013 Sep 29;122(10):1707-11. Epub 2013 Jul 29.

Division of Hematology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA 94305-5821, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2013-05-50
Publisher Site
http://dx.doi.org/10.1182/blood-2013-05-500959DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765056PMC
September 2013

Editorial.

Authors:
Jason Gotlib

Ther Adv Hematol 2013 Aug;4(4):235-6

Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2324, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620713498057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734904PMC
August 2013

ICON: Eosinophil Disorders.

World Allergy Organ J 2012 Dec;5(12):174-81

1Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria 2Eosinophil Pathology Unit, Laboratory of Parasitic Diseases, NIH/NIAID, Bethesda, MD 3Children's Mercy Hospital, Kansas City, MO 4LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France 5Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 6Division of Allergic Diseases, Mayo Clinic, Rochester, MN 7Division of Hematology, Stanford Cancer Center, Stanford, CA 8MLL Münchner Leukämielabor, Munich, Germany 9Department of Hematology, Medical University School of Gdansk, Gdańsk, Poland 10Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany 11Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT 12III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany 13Department of Allergy and Immunology, National Research Institute for Children's Health and Development, Tokyo, Japan 14Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium 15Division of Allergy and Immunology, Cincinnati Children's Hospital, Medical Center, Cincinnati, OH 16Institute of Pharmacology, University of Bern, Bern, Switzerland 17Center for Human Genetics, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium 18Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 19Department of Medicine, University of Utah Health Sciences Center, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WOX.0b013e31827f4192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651188PMC
December 2012

Next-generation sequencing in hematologic malignancies: what will be the dividends?

Ther Adv Hematol 2012 Dec;3(6):333-9

Department of Pathology, Stanford University School of Medicine, Stanford, CA 94304, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620712458948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627325PMC
December 2012